9966 Stock Overview
Alphamab Oncology, a clinical stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of oncology biologics.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Alphamab Oncology Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$5.23 |
| 52 Week High | HK$15.76 |
| 52 Week Low | HK$3.81 |
| Beta | 0.37 |
| 1 Month Change | 20.51% |
| 3 Month Change | 29.14% |
| 1 Year Change | -65.13% |
| 3 Year Change | -64.18% |
| 5 Year Change | n/a |
| Change since IPO | -61.26% |
Recent News & Updates
Recent updates
Optimistic Investors Push Alphamab Oncology (HKG:9966) Shares Up 27% But Growth Is Lacking
Mar 13
Subdued Growth No Barrier To Alphamab Oncology's (HKG:9966) Price
Jan 17Slammed 40% Alphamab Oncology (HKG:9966) Screens Well Here But There Might Be A Catch
May 21Newsflash: Alphamab Oncology (HKG:9966) Analysts Have Been Trimming Their Revenue Forecasts
Mar 01Is Alphamab Oncology (HKG:9966) Using Debt Sensibly?
Oct 04Is Alphamab Oncology (HKG:9966) A Risky Investment?
May 21Rock star Growth Puts Alphamab Oncology (HKG:9966) In A Position To Use Debt
Oct 05Is Alphamab Oncology (HKG:9966) Using Too Much Debt?
May 05How Many Alphamab Oncology (HKG:9966) Shares Have Insiders Sold, In The Last Year?
Feb 09
Should Alphamab Oncology (HKG:9966) Be Disappointed With Their 19% Profit?
Dec 30What Percentage Of Alphamab Oncology (HKG:9966) Shares Do Insiders Own?
Nov 25Shareholder Returns
| 9966 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 17.5% | 4.3% | 2.6% |
| 1Y | -65.1% | -37.2% | -7.4% |
Return vs Industry: 9966 underperformed the Hong Kong Biotechs industry which returned -37.2% over the past year.
Return vs Market: 9966 underperformed the Hong Kong Market which returned -7.4% over the past year.
Price Volatility
| 9966 volatility | |
|---|---|
| 9966 Average Weekly Movement | 9.9% |
| Biotechs Industry Average Movement | 9.4% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in HK Market | 15.0% |
| 10% least volatile stocks in HK Market | 3.6% |
Stable Share Price: 9966's share price has been volatile over the past 3 months.
Volatility Over Time: 9966's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 435 | Ting Xu | www.alphamabonc.com |
Alphamab Oncology, a clinical stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of oncology biologics. Its product pipeline includes KN046, a bispecific monoclonal antibody (BsAb) immune checkpoint inhibitor, which is in Phase III clinical trials that targets clinically-validated immune checkpoints, including programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); and KN026, a next generation anti-human epidermal growth factor receptor 2 (HER2) BsAb that is in Phase II clinical trials for neoadjuvant treatment of HER2-positive breast cancer and I/II clinical trial treatment of heavily pre-treated breast cancers, as well as Phase II clinical trial for HER2-positive solid tumors. The company’s product pipeline also comprises KN019, a CTLA-4-based immunosuppressant fusion protein, which is in Phase II clinical trial for auto-immune diseases and oncology treatment-induced immune disorders; and KN035, an injectable PD-L1 inhibitor that is in phase III clinical trials for advanced solid tumors with deficient mismatch repair/microsatellite instability-high solid tumors, and is in Phase III clinical trials for biliary tract cancer.
Alphamab Oncology Fundamentals Summary
| 9966 fundamental statistics | |
|---|---|
| Market cap | HK$5.05b |
| Earnings (TTM) | -HK$227.31m |
| Revenue (TTM) | HK$236.14m |
21.4x
P/S Ratio-22.2x
P/E RatioIs 9966 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9966 income statement (TTM) | |
|---|---|
| Revenue | CN¥218.77m |
| Cost of Revenue | CN¥55.24m |
| Gross Profit | CN¥163.54m |
| Other Expenses | CN¥374.13m |
| Earnings | -CN¥210.59m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.22 |
| Gross Margin | 74.75% |
| Net Profit Margin | -96.26% |
| Debt/Equity Ratio | 15.0% |
How did 9966 perform over the long term?
See historical performance and comparison